EA201170970A1 - Применение деферипрона для лечения и предупреждения заболеваний глаз, связанных с железом - Google Patents

Применение деферипрона для лечения и предупреждения заболеваний глаз, связанных с железом

Info

Publication number
EA201170970A1
EA201170970A1 EA201170970A EA201170970A EA201170970A1 EA 201170970 A1 EA201170970 A1 EA 201170970A1 EA 201170970 A EA201170970 A EA 201170970A EA 201170970 A EA201170970 A EA 201170970A EA 201170970 A1 EA201170970 A1 EA 201170970A1
Authority
EA
Eurasian Patent Office
Prior art keywords
iron
deferipron
treatment
subject
diseases associated
Prior art date
Application number
EA201170970A
Other languages
English (en)
Inventor
Майкл Спино
Джошуа Лоренс Дунаеф
Original Assignee
Майкл Спино
Джошуа Лоренс Дунаеф
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Майкл Спино, Джошуа Лоренс Дунаеф filed Critical Майкл Спино
Publication of EA201170970A1 publication Critical patent/EA201170970A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Предлагается применение деферипрона, вводимого перорально или местно, для предупреждения повреждения глаз, индуцированного железом. Применение может быть для изготовления лекарственного средства или для способа предупреждения повреждения глаз, индуцированного железом, у субъекта с риском повреждения глаз, индуцированного железом; способ, включающий введение субъекту профилактически эффективного количества деферипрона. Также предлагается применение деферипрона для лечения заболеваний глаз, связанных с железом. Применение может быть для приготовления лекарственного средства или для способа лечения повреждения глаз у субъекта с повреждением глаз, связанным с железом; способ, включающий местное введение субъекту терапевтически эффективного количества деферипрона.
EA201170970A 2009-01-26 2009-11-12 Применение деферипрона для лечения и предупреждения заболеваний глаз, связанных с железом EA201170970A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14724509P 2009-01-26 2009-01-26
PCT/CA2009/001639 WO2010083582A1 (en) 2009-01-26 2009-11-12 Use of deferiprone for treatment and prevention of iron-related eye disorders

Publications (1)

Publication Number Publication Date
EA201170970A1 true EA201170970A1 (ru) 2012-03-30

Family

ID=42355449

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170970A EA201170970A1 (ru) 2009-01-26 2009-11-12 Применение деферипрона для лечения и предупреждения заболеваний глаз, связанных с железом

Country Status (24)

Country Link
US (1) US20130023569A1 (ru)
EP (1) EP2389179A4 (ru)
JP (1) JP5604631B2 (ru)
KR (1) KR20120078667A (ru)
CN (1) CN102348456A (ru)
AP (1) AP2011005843A0 (ru)
AU (1) AU2009338093B2 (ru)
BR (1) BRPI0920492A2 (ru)
CA (1) CA2750599A1 (ru)
CL (1) CL2011001812A1 (ru)
CR (1) CR20110456A (ru)
EA (1) EA201170970A1 (ru)
IL (1) IL214291A (ru)
MA (1) MA33090B1 (ru)
MX (1) MX2011007947A (ru)
MY (1) MY161269A (ru)
NI (1) NI201100148A (ru)
NZ (1) NZ594728A (ru)
PE (1) PE20120515A1 (ru)
SG (1) SG173145A1 (ru)
TN (1) TN2011000366A1 (ru)
UA (1) UA103366C2 (ru)
WO (1) WO2010083582A1 (ru)
ZA (1) ZA201105514B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016205030B2 (en) 2015-01-09 2021-04-01 The Board Of Trustees Of The University Of Illinois Restoring physiology in iron-deficient organisms using small molecules
SG11202003153TA (en) 2017-10-25 2020-05-28 Chiesi Farm Spa Delayed release deferiprone tablets and methods of using the same
US12016851B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
US12016850B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046219A (en) * 1995-01-20 2000-04-04 Cornell Research Foundation, Inc. Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
AUPQ262499A0 (en) * 1999-09-02 1999-09-23 University Of Queensland, The Novel iron chelators
AU2003282337B2 (en) * 2002-11-07 2009-07-16 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
CA2515424A1 (en) * 2003-02-06 2004-08-26 Bioresponse, Llc The combined use of cruciferous indoles and chelators for the treatment of papillomavirus-related conditions
BRPI0708211A2 (pt) * 2006-02-22 2011-05-17 Arnold Munnich o uso de dferiprona e método para tratar e/ou prevenir ataxia de friedreich resultante de mau tratamento intracelular de ferro
CA2683756A1 (en) 2006-04-14 2007-10-25 Prana Biotechnology Limited Method of treatment of age-related macular degeneration(amd)
ITMI20061770A1 (it) * 2006-09-18 2008-03-19 Carlo Ghisalberti Metodo cosmetico di riduzione delle occhiaie
US8501789B2 (en) * 2007-01-19 2013-08-06 The Trustees Of The University Of Pennsylvania Use of salicylaldehyde isonicotinoyl hydrazone (SIH) for protection against retinal disease

Also Published As

Publication number Publication date
MA33090B1 (fr) 2012-03-01
EP2389179A4 (en) 2012-08-29
AU2009338093B2 (en) 2014-08-28
NI201100148A (es) 2012-03-06
AP2011005843A0 (en) 2011-08-31
CN102348456A (zh) 2012-02-08
CA2750599A1 (en) 2010-07-29
CL2011001812A1 (es) 2012-02-03
AU2009338093A1 (en) 2011-09-08
IL214291A0 (en) 2011-09-27
US20130023569A1 (en) 2013-01-24
MY161269A (en) 2017-04-14
TN2011000366A1 (en) 2013-03-27
BRPI0920492A2 (pt) 2019-07-09
NZ594728A (en) 2013-03-28
JP2012515725A (ja) 2012-07-12
UA103366C2 (ru) 2013-10-10
JP5604631B2 (ja) 2014-10-08
IL214291A (en) 2015-03-31
MX2011007947A (es) 2011-12-14
PE20120515A1 (es) 2012-05-20
WO2010083582A1 (en) 2010-07-29
SG173145A1 (en) 2011-08-29
KR20120078667A (ko) 2012-07-10
CR20110456A (es) 2012-05-31
ZA201105514B (en) 2012-10-31
EP2389179A1 (en) 2011-11-30

Similar Documents

Publication Publication Date Title
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
AU2016202421B2 (en) Method of treating neurological conditions with cardiac glycosides
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
WO2015054619A3 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
NZ714963A (en) Compositions and methods for treating anemia
WO2006098603A3 (en) Composition comprising isoorientin for suppressing histamine
PH12014501491A1 (en) Subcutaneous therapeutic use of dpp-4 inhibitor
EA201391108A1 (ru) Лечение липодистрофии
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
WO2012050831A3 (en) Combination treatment for dermatological conditions
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
WO2014134583A3 (en) Methods of treatment of human cytomegalovirus infection and diseases with bromodomain inhibitors
WO2012044090A3 (ko) 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물
RU2014150942A (ru) Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
MX2013008715A (es) Uso de (s) -esmolol para controlar la irritacion venosa asociada con el tratamiento de un padecimiento cardiaco.
MY183526A (en) Orally administrable pharmaceutical composition for prevention or treatment of dry eye syndrome, comprising rebamipide or prodrug thereof
EA201170970A1 (ru) Применение деферипрона для лечения и предупреждения заболеваний глаз, связанных с железом
WO2008031835A3 (en) Method of treating autoimmune diseases using vegf-pathway inhibitors
CA2866819C (en) Method for treating inflammation
WO2014107685A3 (en) Compositions and methods for using huperzine and analogs thereof
MX348723B (es) Combinaciones de solifenacina y estimulantes salivales para el tratamiento de la vejiga hiperactiva.
CA2863829A1 (en) Oral unit dosage forms and uses of same for the treatment of gaucher disease
EA201071350A1 (ru) Композиции и способы для лечения воспаления роговицы